Study guide
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care
Key Takeaways Explain This Topic AI
Inpatient glycemic target for most critically ill patients is 140-180 mg/dL; NICE-SUGAR showed higher 90-day mortality with an 81-108 mg/dL target, so tight control is superseded practice.
In DKA, delay insulin and replace potassium at about 10 mmol/hr if the serum potassium is below 3.5 mmol/L (2024 ADA/EASD/AACE consensus); the endpoint of the insulin infusion is ketone clearance below 0.6 mmol/L with venous pH 7.3 or above or bicarbonate 18 mmol/L or above — the consensus explicitly retired the anion gap as a resolution criterion because large-volume saline causes a hyperchloremic acidosis that keeps it open.
Give the first dose of subcutaneous basal insulin 2-4 hours before stopping an IV insulin infusion; sliding-scale insulin alone is inadequate because it is purely reactive.
Cardiac autonomic neuropathy produces silent or atypical infarction, resting tachycardia of 90-100, and blunted chronotropic response, so ECG and troponin trends outweigh the diabetic patient's symptom report.
Pioglitazone causes fluid retention and is contraindicated in NYHA class III-IV heart failure, while SGLT2 inhibitors and GLP-1 receptor agonists reduce cardiovascular events and should not be stopped for glycemic reasons alone.
Last updated: October 2026
Why Diabetes Is a Cardiac Diagnosis
Roughly one in three patients admitted with an acute coronary syndrome (ACS) carries a diagnosis of diabetes mellitus , and another large fraction has undiagnosed hyperglycemia discovered on admission. The CMC test plan lists diabetes under Non-Cardiovascular Conditions, but on the exam it is almost never tested as pure endocrinology — it is tested as a modifier of cardiac presentation, cardiac risk, and cardiac drug therapy.
Diabetes has historically been described as a coronary risk equivalent : the untreated 10-year event rate approximates that of a patient who has already had a myocardial infarction (MI). Contemporary guidelines have softened the absolute equivalence — risk varies with duration, albuminuria, and glycemic control — but the practical implication is unchanged. A patient with diabetes and any ischemic symptom is a high-risk patient until proven otherwise, and diabetes is a risk enhancer that pushes borderline and intermediate ASCVD risk toward statin therapy.
Atypical and silent ischemia
Cardiac autonomic neuropathy (CAN) is the mechanism behind the most heavily tested clinical pearl in this area. Damage to the afferent sympathetic fibers that carry anginal pain blunts or abolishes the classic substernal pressure. The diabetic patient with an evolving infarct is far more likely to present with:
- dyspnea or new orthostatic intolerance rather than chest pain
- nausea, vomiting, or epigastric discomfort mistaken for gastroenteritis
- profound fatigue, confusion, or a new fall in an older adult
- unexplained hyperglycemia or new DKA as the only signal of infarction
CAN also produces a resting tachycardia of 90 to 100 beats per minute, a fixed heart rate that fails to vary with respiration or position, orthostatic hypotension without a compensatory heart rate rise, and blunted heart rate response during exercise testing. Practically: a diabetic patient whose heart rate does not accelerate appropriately during a stress test has an abnormal chronotropic response, not a "good baseline." Silent ischemia means the nurse must rely on the monitor, the 12-lead, and troponin trends rather than on the patient's symptom report. Continuous ST-segment monitoring in the correct lead has more value in this population than in almost any other.
Worse outcomes and revascularization strategy
Diabetic patients have more diffuse, distal, multivessel disease with smaller reference vessel diameters, more calcification, more left main involvement, and a higher burden of microvascular disease. Consequences the CMC exam expects you to know:
higher rates of in-stent restenosis and target-vessel revascularization after percutaneous coronary intervention (PCI)
higher rates of heart failure, cardiogenic shock, and death after MI
CABG is preferred over multivessel PCI in most diabetic patients with multivessel disease. The FREEDOM trial demonstrated lower death and MI with coronary artery bypass grafting compared with drug-eluting stents; ACC/AHA revascularization guidance gives CABG a stronger recommendation in diabetics with multivessel disease and suitable anatomy, particularly with a left internal mammary artery graft to the left anterior descending.
diabetic cardiomyopathy: diastolic dysfunction and heart failure with preserved ejection fraction develop independently of epicardial coronary disease.
- Inpatient Glycemic Control in the Cardiac ICU
- The target, and the trials that set it
The current American Diabetes Association Standards of Care target for most critically ill hospitalized patients is a glucose of 140 to 180 mg/dL , with therapy initiated at a persistent glucose above 180 mg/dL. A tighter range of 110 to 140 mg/dL is acceptable only in selected patients if it can be achieved without significant hypoglycemia.
Know the history, because it is a favorite distractor. A landmark single-center surgical ICU trial reported a mortality benefit from intensive insulin therapy targeting 80 to 110 mg/dL, and tight control briefly became standard. The multicenter NICE-SUGAR trial then randomized more than 6,000 ICU patients and found higher 90-day mortality with the 81 to 108 mg/dL target compared with a target at or below 180 mg/dL, driven substantially by severe hypoglycemia. Tight glycemic control in critical illness is superseded practice. If an option says "titrate to 80 to 110 mg/dL," it is wrong.
Intravenous insulin infusion and the transition off it
Continuous IV regular insulin is the preferred approach for critically ill patients, patients on vasopressors, patients with unstable perfusion and unreliable subcutaneous absorption, and hyperglycemic emergencies. Practice points:
Use a validated, nurse-driven or computerized titration protocol, not ad hoc dosing. Point-of-care glucose hourly until stable for 3 to 4 consecutive readings, then every 2 hours.
Verify glucose with a laboratory or blood gas value when perfusion is poor, when the patient is on high-dose vasopressors, or when the point-of-care value conflicts with the clinical picture — capillary samples are unreliable in shock, edema, and severe anemia.
Anticipate rising requirements with corticosteroids, dextrose-containing infusions, enteral or parenteral nutrition, and vasopressors; anticipate falling requirements when nutrition is held for a procedure. Never stop the tube feeding and leave the insulin infusion running unchanged.
Transition to subcutaneous therapy is the single most common source of iatrogenic hyperglycemia and DKA relapse. Administer the first dose of basal insulin 2 to 4 hours before discontinuing the drip (glargine or detemir need roughly 2 to 4 hours to take effect; a rapid-acting analog needs 1 to 2 hours of overlap). Estimate the 24-hour requirement from the average stable infusion rate over the previous 6 to 8 hours, multiply by 24, and give roughly 60 to 80 percent of that total as the subcutaneous dose, split about half basal and half prandial.
Basal-bolus versus sliding scale
A basal-bolus-correction regimen — a long-acting basal insulin, scheduled prandial coverage matched to nutrition, and a correction scale — is the standard for non-critically-ill inpatients. Sliding-scale insulin as the sole regimen is explicitly discouraged. It is purely reactive, it treats hyperglycemia only after it occurs, it produces oscillating glucose, and randomized inpatient data showed better control with basal-bolus and no excess hypoglycemia. If the patient is NPO, continue basal insulin (often at 50 to 80 percent of the usual dose) and hold prandial insulin — do not hold everything.
Hypoglycemia and the beta-blocker problem
Level 1 hypoglycemia is a glucose below 70 mg/dL ; level 2 (clinically significant) is below 54 mg/dL ; level 3 is severe hypoglycemia with altered mental status requiring assistance. Nearly every cardiac patient is on a beta blocker , which blunts the adrenergic warning signs — tremor, palpitations, tachycardia, anxiety — that normally alert the patient and the nurse. Diaphoresis is cholinergically mediated and is preserved , so unexplained sweating in a beta-blocked diabetic patient is hypoglycemia until a glucose disproves it. Non-selective agents can also impair hepatic glycogenolysis and prolong recovery.
Treat with 15 to 20 g of oral carbohydrate if the patient can swallow safely, or dextrose 50% 25 mL IV (12.5 g) if there is IV access and the patient is obtunded, or glucagon 1 mg IM/SC if there is no access. Recheck in 15 minutes and repeat until above 70 mg/dL, then give a complex carbohydrate and protein. Hypoglycemia is itself arrhythmogenic — catecholamine surge, QT prolongation, and hypokalemia — and in ACS it is independently associated with worse outcomes.
Hyperglycemic Emergencies
- Feature Diabetic ketoacidosis (DKA) Hyperosmolar hyperglycemic state (HHS)
- Typical patient Type 1, or type 2 under severe stress Type 2, older, often nursing-home resident
- Onset Hours to 1-2 days Days to weeks
- Plasma glucose 200 mg/dL or above, or known diabetes (under 200 in euglycemic DKA) Above 600 mg/dL
- Arterial pH Below 7.30 Above 7.30
- Serum bicarbonate 18 mEq/L or less Above 18 mEq/L
- Ketones / beta-hydroxybutyrate Moderate to large Absent to trace
- Anion gap Elevated, above 10-12 Normal or minimally raised
- Effective serum osmolality Variable Above 320 mOsm/kg
- Mental status Alert to drowsy Stupor to coma
- Fluid deficit About 100 mL/kg (6-8 L) About 100-150 mL/kg (8-12 L)
- Mortality 1-5% 10-20%
Precipitants are the same list a cardiac nurse should already own: infection (most common), missed insulin, myocardial infarction, stroke, pancreatitis, corticosteroids, and SGLT2 inhibitors.
The treatment sequence
Fluids first. Isotonic 0.9% sodium chloride or a balanced crystalloid at 500 to 1,000 mL/hr for the first 2 to 4 hours in adults without renal or cardiac compromise (2024 adult consensus), then by hydration status. After the first hour, use the corrected sodium to choose the next fluid: if corrected sodium is normal or high, switch to 0.45% sodium chloride; if it is low, continue 0.9%. Balanced crystalloids are an acceptable alternative and may close the gap faster with less hyperchloremic acidosis.
Check potassium before insulin. This is the highest-yield rule in the section. Total-body potassium is depleted by 3 to 5 mEq/kg even when the serum value looks normal or high, because acidosis and insulin deficiency drive potassium out of cells. Insulin drives it straight back in.
Potassium below 3.5 mEq/L: hold insulin and replace potassium at about 10 mEq/hr until above 3.5. Starting insulin here can precipitate fatal arrhythmia or respiratory muscle weakness.
Potassium 3.5 to 5.0 mEq/L: add 20 to 30 mEq to each liter of fluid and start insulin.
Potassium above 5.0 mEq/L: withhold potassium until it falls below 5.0, start insulin, and recheck 2 hours after insulin starts, then every 4 hours.
Insulin. Regular insulin 0.1 unit/kg IV bolus then 0.1 unit/kg/hr, or 0.14 unit/kg/hr infusion with no bolus. Target a fall of 50 to 75 mg/dL per hour . When glucose falls below 250 mg/dL in DKA (250 to 300 mg/dL in HHS), add 5-10% dextrose to the infusion and reduce the insulin rate — you continue insulin to close the gap, not to lower the glucose.
Endpoint. Per the 2024 ADA/EASD/AACE/JBDS/DTS consensus, DKA is resolved when the plasma ketone falls below 0.6 mmol/L and the venous pH is 7.3 or above, or bicarbonate 18 mmol/L or above — not when the glucose normalizes. The consensus explicitly states the anion gap should not be used as a resolution criterion, because the large volumes of 0.9% sodium chloride used in resuscitation produce a hyperchloremic acidosis that holds the gap open after the ketosis has cleared. Overlap subcutaneous basal insulin 1 to 2 hours before stopping the drip. Stopping the infusion at a normal glucose with an open gap is the classic relapse mechanism.
Adjuncts. Routine bicarbonate is not recommended; consider it only if pH is below 7.0. Phosphate replacement only if the level falls below 1.0 mg/dL or there is cardiac dysfunction, respiratory depression, or hemolysis — cardiac patients are exactly the group in whom this matters, but routine repletion causes hypocalcemia.
Cardiac-specific cautions
In a patient with heart failure with reduced ejection fraction, end-stage renal disease, or a recent infarct, the standard 500 to 1,000 mL/hr resuscitation rate can produce flash pulmonary edema. Give smaller boluses (for example, 250 mL) with reassessment after each, as the 2024 adult consensus advises, use point-of-care ultrasound or filling pressures to guide, watch for a rising oxygen requirement and new crackles, and consider that dialysis-dependent patients may need very little volume at all. Correct potassium and glucose with continuous ECG monitoring — the combination of shifting potassium, magnesium, and phosphate is highly arrhythmogenic. Cerebral edema is chiefly a pediatric complication but argues against overly rapid osmolar correction in any patient.
Euglycemic DKA and SGLT2 inhibitors
Sodium-glucose cotransporter-2 (SGLT2) inhibitors — empagliflozin, dapagliflozin, canagliflozin, ertugliflozin — cause glycosuria and can produce a wide-anion-gap ketoacidosis with a glucose below 200 mg/dL. This is a trap in cardiac care because SGLT2 inhibitors are now foundational heart-failure therapy given to patients who may not even have diabetes. Suspect it in any acidotic patient on one of these drugs, and measure serum beta-hydroxybutyrate rather than urine ketones (the nitroprusside urine test detects acetoacetate and underestimates beta-hydroxybutyrate). Treatment is the same insulin-plus-dextrose approach, often requiring dextrose from the outset. Hold SGLT2 inhibitors 3 days before major or elective surgery (4 days for ertugliflozin) and during acute illness with poor oral intake.
Antidiabetic Drugs Through a Cardiac Lens
Drug class Cardiovascular relevance Nursing/monitoring priority
Metformin No hypoglycemia, weight-neutral, first-line; lactic acidosis risk with tissue hypoperfusion Contraindicated if eGFR under 30; hold at the time of iodinated contrast if eGFR is under 30, with AKI, or with an intra-arterial study, and recheck renal function before restarting after 48 hours. Hold in shock, sepsis, decompensated heart failure
SGLT2 inhibitors (empagliflozin, dapagliflozin) Proven reduction in heart failure hospitalization and CV death across the ejection fraction spectrum and in CKD; guideline-directed therapy in HFrEF and HFpEF Volume depletion and hypotension when combined with diuretics, genital mycotic infection, euglycemic DKA, modest early creatinine rise that is expected and not a reason to stop
GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) Reduced major adverse cardiovascular events in type 2 diabetes with established ASCVD; weight loss and blood pressure reduction Nausea and vomiting, delayed gastric emptying with aspiration risk during sedation or intubation, pancreatitis, not for type 1 diabetes or DKA
Dual GIP/GLP-1 agonist (tirzepatide) Large weight reduction; benefit in obesity-related HFpEF Same GI and periprocedural gastric-emptying cautions
Thiazolidinediones (pioglitazone) Causes sodium and fluid retention, peripheral edema, and weight gain; precipitates or worsens heart failure Contraindicated in NYHA class III-IV heart failure and to be avoided in any symptomatic heart failure. A new 4 kg weight gain with edema on pioglitazone is drug-induced volume overload
Sulfonylureas (glipizide, glyburide) Real hypoglycemia risk, prolonged in renal impairment and with beta blockade masking symptoms Glyburide has the longest duration and the highest hypoglycemia risk in older adults and CKD; hold when NPO
DPP-4 inhibitors (sitagliptin, saxagliptin) Glucose-neutral for MACE; saxagliptin and alogliptin were associated with increased heart-failure hospitalization Reasonable to avoid saxagliptin in heart failure
Insulin Effective at any level of renal function; associated with fluid retention and weight gain Hypoglycemia is the dose-limiting toxicity; never use the sliding scale alone
Long-term glycemic targets and discharge teaching
A general A1c target below 7 percent applies to most adults; a value of 7 percent corresponds to an estimated average glucose of about 154 mg/dL. Individualize upward to below 8 percent for patients with limited life expectancy, advanced complications, extensive comorbidity, hypoglycemia unawareness, or a long history of difficult control — pushing an 80-year-old with three-vessel disease and CKD to an A1c of 6.5 percent buys hypoglycemia, not longevity. Check A1c on admission for any cardiac patient with hyperglycemia and no recent value; it distinguishes stress hyperglycemia from previously undiagnosed diabetes and shapes the discharge regimen.
Nursing education at discharge should cover sick-day rules (never omit basal insulin, check glucose and ketones every 4 hours, maintain hydration), hypoglycemia recognition despite beta blockade, glucose meter or continuous glucose monitor technique, insulin injection site rotation, statin adherence, a blood-pressure goal below 130/80 mm Hg, foot inspection, and — the piece most often omitted — that SGLT2 inhibitors and GLP-1 agonists are being continued for cardiac benefit even if the glucose looks fine, so they should not be stopped by an outside prescriber.